We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.29B
1-Year Est. Return 141.72%
This Fund
S&P 500
This Quarter Est. Return
+6.98%
1 Year Est. Return
+141.72%
3 Year Est. Return
+440.65%
5 Year Est. Return
+290.21%
10 Year Est. Return
–
AUM
$577M
AUM Growth
-$4.53M
Cap. Flow
+$3.09M
Cap. Flow %
0.53%
Top 10 Hldgs %
45.32%
Holding
51
New
8
Increased
10
Reduced
20
Closed
7

Top Buys

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$15.9M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$15.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$13.7M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$11.6M
5
DBVT
DBV Technologies
DBVT
+$9.33M

Top Sells

Rank Stock Value
1
LNTH icon
Lantheus
LNTH
+$22.7M
2
UTHR icon
United Therapeutics
UTHR
+$18.2M
3
ITOS
iTeos Therapeutics
ITOS
+$10.4M
4
TWST icon
Twist Bioscience
TWST
+$10.3M
5
NTRA icon
Natera
NTRA
+$9.06M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
26
Wave Life Sciences
WVE
$1.12B
$9.78M 1.7%
1,505,262
-4,318
-0.3% -$28.5K
DBVT
27
DBV Technologies
DBVT
$813M
$9.65M 1.67%
+1,054,504
New +$9.33M
CNTX icon
28
Context Therapeutics
CNTX
$56.7M
$9.64M 1.67%
14,705,882
– –
RCKT icon
29
Rocket Pharmaceuticals
RCKT
$343M
$9.56M 1.66%
3,903,081
+2,284,816
+141% +$11.6M
REPL icon
30
Replimune Group
REPL
$454M
$9.14M 1.58%
983,780
-3,256
-0.3% -$28.4K
NUVB icon
31
Nuvation Bio
NUVB
$2.29B
$9.01M 1.56%
4,622,590
-29,653
-0.6% -$61.8K
STOK icon
32
Stoke Therapeutics
STOK
$1.84B
$8.96M 1.55%
789,698
+95,710
+14% +$909K
SLDB icon
33
Solid Biosciences
SLDB
$792M
$7.96M 1.38%
1,634,569
-7,787
-0.5% -$27.5K
RLAY icon
34
Relay Therapeutics
RLAY
$4B
$7.9M 1.37%
2,282,680
-13,244
-0.6% -$39.4K
RNAC icon
35
Cartesian Therapeutics
RNAC
$218M
$7.13M 1.24%
686,007
-104,772
-13% -$1.12M
TSHA icon
36
Taysha Gene Therapies
TSHA
$1.61B
$6.82M 1.18%
+2,953,562
New +$6.42M
SRPT icon
37
Sarepta Therapeutics
SRPT
$1.64B
$5.5M 0.95%
+321,696
New +$13.7M
SLNO
38
DELISTED
Soleno Therapeutics
SLNO
$4.19M 0.73%
+50,000
New +$3.74M
VERU icon
39
Veru
VERU
$35.5M
$2.86M 0.5%
491,195
-168,078
-25% -$944K
HOWL icon
40
Werewolf Therapeutics
HOWL
$22.4M
$2.63M 0.45%
2,408,810
– –
DSGN icon
41
Design Therapeutics
DSGN
$751M
$1.87M 0.32%
555,187
-7,756
-1% -$29K
RPTX
42
DELISTED
Repare Therapeutics
RPTX
$1.14M 0.2%
819,924
– –
ADAP
43
DELISTED
Adaptimmune Therapeutics
ADAP
$1.06M 0.18%
4,411,821
-482,523
-10% -$129K
ACLX
44
DELISTED
Arcellx
ACLX
$2.44K ﹤0.01%
+37
New +$2.3K
ALXO icon
45
ALX Oncology
ALXO
$262M
– –
-550,000
Closed -$343K
IDYA icon
46
IDEAYA Biosciences
IDYA
$3.43B
– –
-430,161
Closed -$7.05M
IOVA icon
47
Iovance Biotherapeutics
IOVA
$2.04B
– –
-2,708,582
Closed -$9.02M
ITOS
48
DELISTED
iTeos Therapeutics
ITOS
– –
-1,745,943
Closed -$10.4M
LNTH icon
49
Lantheus
LNTH
$6.51B
– –
-232,387
Closed -$22.7M
TWST icon
50
Twist Bioscience
TWST
$5.32B
– –
-261,215
Closed -$10.3M
1
2
3

Similar funds

MCM
Mainstay Capital Management Grand Blanc, Michigan $1.3B AUM 37.8% 1-Year Est. Return
PWP
Private Wealth Partners Mill Valley, California $1.3B AUM 26.2% 1-Year Est. Return
GPCM
Greenbrier Partners Capital Management Dallas, Texas $1.3B AUM 21.43% 1-Year Est. Return
PR
Payden & Rygel Los Angeles, California $1.3B AUM 28.32% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
COCM
Charter Oak Capital Management Portsmouth, New Hampshire $1.29B AUM 13.93% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.29B AUM 18.01% 1-Year Est. Return

MPM BioImpact's Q2 2025 Portfolio in Review

As of Q2 2025, MPM BioImpact held 51 positions worth $577M, down 0.78% from $582M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

MPM BioImpact's Q2 2025 filing shows 8 new, 10 increased, 20 reduced and 7 closed positions. Its largest new stake was Dyne Therapeutics: 1,446,361 shares worth $13.8M. The largest sale was Lantheus, an estimated $22.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q2 2025 buy was Dyne Therapeutics: 1,446,361 shares worth $13.8M.
  • MPM BioImpact added most to Rocket Pharmaceuticals in Q2 2025, an estimated $11.6M increase.
  • MPM BioImpact's biggest Q2 2025 reduction was Natera, cutting an estimated $9.06M.
  • MPM BioImpact fully exited Lantheus in Q2 2025, selling an estimated $22.7M.
  • MPM BioImpact's ten largest holdings make up 45% of its $577M portfolio in Q2 2025.
  • MPM BioImpact opened 8 new positions and closed 7 in Q2 2025.
  • MPM BioImpact's portfolio value fell 0.78% quarter-over-quarter to $577M.

Based on MPM BioImpact's 13F filing for Q2 2025, filed 14 Aug 2025.